Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

clinical trial

MedicalStudy clinical_trial Q61914940

Press Enter · cited answer in seconds

Summary

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients is a clinical trial^[1].

Key Facts

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's instance of is recorded as clinical trial^[2].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's start time is recorded as +2008-05-31T00:00:00Z^[3].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's end time is recorded as +2010-05-31T00:00:00Z^[4].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's sponsor is recorded as GSK^[5].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's main subject is recorded as multiple sclerosis^[6].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's main subject is recorded as sclerosis^[7].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's number of participants is recorded as {'unit': '1', 'amount': '+38'}^[8].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's title is recorded as A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients^[9].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's short name is recorded as OMS115102^[10].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's ClinicalTrials.gov ID is recorded as NCT00640328^[12].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+55'}^[13].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's research intervention is recorded as ofatumumab^[14].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's clinical trial phase is recorded as phase II clinical trial^[15].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's research subject recruitment status is recorded as completed^[16].
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients's study type is recorded as interventional study^[17].

⭐ Popularity Graph

0/100 long tail

⛏️ Lake Facts · open-dataset statements via 4ort-mint

From open datasets, joined by identifier and shown only for properties Wikidata does not state on this entity — except where the dataset is the registry authority for the fact (ClinicalTrials.gov on trial registration data): there its value is shown instead, with Wikidata's noted beside it. Every row carries its dataset edition and licence.

End timeP582

2011-10 2026-09-26 Wikidata lists 2010-05-31 ClinicalTrials.gov (US Government Public Domain)

Medical conditionP1050

multiple sclerosis 2026-09-26 ClinicalTrials.gov (US Government Public Domain)

ClinicalTrials.gov (data processed by ClinicalTrials.gov on 2026-09-26); U.S. federal government data, public domain; lake licence_code custom-review

Quick Facts

Instance of clinical trial

Short name OMS115102

Properties

Clinical trial phase phase II clinical trial

End time May 31, 2010

Imported from wholeness_audit_2026-05-02

Main subject multiple sclerosis, sclerosis

Maximum age 55 year

Minimum age 18 year

Number of participants 38

Research intervention ofatumumab

Research subject recruitment status completed

Sponsor GSK

Start time May 31, 2008

Study type interventional study

Title A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

External References (1)

Clinicaltrials.gov id NCT00640328

🏷️ Also known as

en Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

Class ancestry

[1] ↑ Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients is an instance of clinical trial (Q30612) [P31, primary]. Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA

4ort.xyz Knowledge Graph. (2026). Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients. Retrieved May 3, 2026, from https://4ort.xyz/entity/ofatumumab-dose-finding-in-relapsing-remitting-multiple-sclerosis-rrms-patients

MLA

“Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/ofatumumab-dose-finding-in-relapsing-remitting-multiple-sclerosis-rrms-patients.

BibTeX

@misc{4ortxyz_ofatumumab-dose-finding-in-relapsing-remitting-multiple-sclerosis-rrms-patients_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients}}, year = {2026}, url = {https://4ort.xyz/entity/ofatumumab-dose-finding-in-relapsing-remitting-multiple-sclerosis-rrms-patients}, note = {Accessed: 2026-05-03}}

LLM prompt

According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients — https://4ort.xyz/entity/ofatumumab-dose-finding-in-relapsing-remitting-multiple-sclerosis-rrms-patients (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/ofatumumab-dose-finding-in-relapsing-remitting-multiple-sclerosis-rrms-patients · Last refreshed: May 3, 2026